GENETIC TECHNOLOGIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.12 AUD | -7.69% |
|
0.00% | -11.11% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 9.22M 6.09M | Sales 2023 | 10.35M 6.83M | Capitalization | 28.85M 19.05M |
|---|---|---|---|---|---|
| Net income 2022 | -7M -4.62M | Net income 2023 | -11M -7.26M | EV / Sales 2022 | 1.8 x |
| Net cash position 2022 | 11.09M 7.32M | Net cash position 2023 | 7.34M 4.84M | EV / Sales 2023 | 2.08 x |
| P/E ratio 2022 |
-3.88
x | P/E ratio 2023 |
-2.16
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 88.17% |
More Fundamentals
* Assessed data
More news
Latest transcript on Genetic Technologies Limited
More press releases
| 1 day | -7.69% | ||
| Current month | +9.09% | ||
| 1 month | -31.43% | ||
| 3 months | +14.29% | ||
| 6 months | -40.00% | ||
| Current year | -11.11% |
1 week
0.12
0.14
1 month
0.110.18
Current year
0.090.19
1 year
0.090.30
3 years
0.091.10
5 years
0.091.40
10 years
0.099.10
| Managers | Title | Age | Since |
|---|---|---|---|
Simon Morriss
CEO | Chief Executive Officer | - | 21-01-31 |
Erika Spaeth
CTO | Chief Tech/Sci/R&D Officer | - | 15-12-31 |
Jerzy Muchnicki
BRD | Director/Board Member | - | 18-01-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 65 | 14-09-23 | |
| Chairman | - | 18-01-30 | |
Jerzy Muchnicki
BRD | Director/Board Member | - | 18-01-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 0.12 | -7.69% | 33,852 |
| 24-05-09 | 0.13 | 0.00% | 70,048 |
| 24-05-08 | 0.13 | 0.00% | 73,760 |
| 24-05-07 | 0.13 | +8.33% | 29,132 |
| 24-05-06 | 0.12 | 0.00% | 153,277 |
Delayed Quote Australian S.E., May 10, 2024 at 01:47 am EDT
More quotes
Genetic Technologies Limited is an Australia-based diversified molecular diagnostics company. The Company is engaged in providing genomics-based tests on health, wellness and serious disease through its geneType and EasyDNA brands. The Company offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that integrates clinical and genetic risk to deliver outcomes to physicians and individuals. The Company operates through three segments: EasyDNA, AffinityDNA, and GeneType / Corporate. EasyDNA segment relates to EasyDNA branded test sales and expenses. AffinityDNA segment relates to AffinityDNA branded test sales and expenses. GeneType / Corporate segment relates to geneType branded test sales and expenses, including corporate charges. The GeneType test is for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and mor
Calendar
2024-08-28
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -11.11% | 10.48M | |
| +20.68% | 85.55B | |
| -29.31% | 70.07B | |
| +9.65% | 29.06B | |
| -8.63% | 17.51B | |
| +2.14% | 17.39B | |
| +0.39% | 15.38B | |
| +6.47% | 13.4B | |
| +68.23% | 12.42B | |
| +6.43% | 12.77B |
- Stock Market
- Equities
- GTG Stock
